当前位置: 首页 >> 检索结果
361. Suppression of soluble T cell-associated proteins by an anti-interferon-α monoclonal antibody in adult patients with dermatomyositis or polymyositis.
作者: Xiang Guo.;Brandon W Higgs.;Marlon Rebelatto.;Wei Zhu.;Warren Greth.;Yihong Yao.;Lorin K Roskos.;Wendy I White.
来源: Rheumatology (Oxford). 2014年53卷4期686-95页
The aim of this study was to identify serum markers that are modulated by an investigational anti-IFN-α mAb, sifalimumab, in adult DM or PM patients.
362. Head-to-head comparison of udenafil vs amlodipine in the treatment of secondary Raynaud's phenomenon: a double-blind, randomized, cross-over study.
作者: Eun Young Lee.;Jin Kyun Park.;Whal Lee.;Yeo Koon Kim.;Claire Su-Yeon Park.;Jon T Giles.;Jun Won Park.;Kichul Shin.;Jeong Seok Lee.;Yeong Wook Song.;Eun Bong Lee.
来源: Rheumatology (Oxford). 2014年53卷4期658-64页
RP is a reversible vasoconstriction of digital arteries that causes pain and skin discoloration. This study compared the efficacy of the new phosphodiesterase type 5 inhibitor udenafil with that of the calcium channel blocker amlodipine in the treatment of secondary RP.
363. Epratuzumab for patients with moderate to severe flaring SLE: health-related quality of life outcomes and corticosteroid use in the randomized controlled ALLEVIATE trials and extension study SL0006.
作者: Vibeke Strand.;Michelle Petri.;Kenneth Kalunian.;Caroline Gordon.;Daniel J Wallace.;Kathryn Hobbs.;Lexy Kelley.;Brian Kilgallen.;William A Wegener.;David M Goldenberg.
来源: Rheumatology (Oxford). 2014年53卷3期502-11页
To evaluate health-related quality of life (HRQOL) and corticosteroid use in patients with moderate to severely active SLE enrolled in two international, multicentre, randomized controlled trials of epratuzumab (ALLEVIATE-1 and -2) and a long-term extension study (SL0006).
365. Low-dose aspirin vs low-dose aspirin plus low-intensity warfarin in thromboprophylaxis: a prospective, multicentre, randomized, open, controlled trial in patients positive for antiphospholipid antibodies (ALIWAPAS).
作者: Maria J Cuadrado.;Maria L Bertolaccini.;Paul T Seed.;Maria G Tektonidou.;Angeles Aguirre.;Luisa Mico.;Caroline Gordon.;Guillermo Ruiz-Irastorza.;Maria V Egurbide.;Antonio Gil.;Gerard Espinosa.;Frederic Houssiau.;Anisur Rahman.;Helena Martin.;Neil McHugh.;Maria Galindo.;Mohammed Akil.;Mary C Amigo.;Veronica Murru.;Munther A Khamashta.
来源: Rheumatology (Oxford). 2014年53卷2期275-84页
The objectives of this study are to examine the efficacy and safety of low-dose aspirin (LDA) vs LDA plus low-intensity warfarin (LDA + W) in the primary thrombosis prevention of aPL-positive patients with SLE and/or obstetric morbidity and the role of clinical and serological markers in the development of thrombosis.
366. Bisphosphonates vs infliximab in ankylosing spondylitis treatment.
作者: Ombretta Viapiana.;Davide Gatti.;Luca Idolazzi.;Elena Fracassi.;Silvano Adami.;Sonila Troplini.;Maria Rosaria Povino.;Maurizio Rossini.
来源: Rheumatology (Oxford). 2014年53卷1期90-4页
The objective of this study was to evaluate if the anti-inflammatory properties of bisphosphonates and their effect on bone turnover could be useful in the treatment of AS.
367. Predictors of self-reported health-related quality of life in systemic lupus erythematosus.
作者: Adnan N Kiani.;Vibeke Strand.;Hong Fang.;Jawali Jaranilla.;Michelle Petri.
来源: Rheumatology (Oxford). 2013年52卷9期1651-7页
The Medical Outcomes Short Form-36 Survey (SF-36) has been widely used as a measure of health-related quality of life (HRQOL) in different populations. SLE patients have consistently reported lower scores compared with the general population. The objective of our study was to identify predictors of HRQOL using SF-36 among patients with SLE enrolled in a 2-year randomized controlled trial (RCT).
368. Cost-effectiveness of exercise therapy after corticosteroid injection for moderate to severe shoulder pain due to subacromial impingement syndrome: a trial-based analysis.
作者: Sue Jowett.;Dickon P Crawshaw.;Philip S Helliwell.;Elizabeth M A Hensor.;Elaine M Hay.;Philip G Conaghan.
来源: Rheumatology (Oxford). 2013年52卷8期1485-91页
To perform a cost-effectiveness analysis of subacromial corticosteroid injection combined with exercise compared with exercise alone in patients with moderate to severe shoulder pain from subacromial impingement syndrome.
369. A simple model that suggests possible cost savings when modified-release prednisone 5 mg/day is added to current treatment in patients with active rheumatoid arthritis.
The effects of a 12-week treatment with modified-release prednisone (MR-pred) on the costs of drug treatment of RA were modelled.
370. A multicentre, randomized, placebo- and active-controlled trial comparing the efficacy and safety of topical ketoprofen in Transfersome gel (IDEA-033) with ketoprofen-free vehicle (TDT 064) and oral celecoxib for knee pain associated with osteoarthritis.
作者: Philip G Conaghan.;John Dickson.;Wolfgang Bolten.;Gregor Cevc.;Matthias Rother.
来源: Rheumatology (Oxford). 2013年52卷7期1303-12页
To assess the efficacy and safety of 12-week treatment with ketoprofen in ultradeformable phospholipid vesicles in patients with OA knee pain and to compare the efficacy with that of ketoprofen-free vehicle and celecoxib. METHODS; A multicentre, double-blind controlled study in which patients with knee OA and moderate pain were randomized to one of the six arms: topical ketoprofen 50 or 100 mg in ultradeformable vesicles (IDEA-033), 2.2 or 4.4 g ketoprofen-free vehicle (TDT 064), oral celecoxib 100 mg or matching oral placebo, all bd. The primary outcome was change from baseline in the WOMAC pain subscale at week 12.
371. Efficacy and safety of epratuzumab in patients with moderate/severe flaring systemic lupus erythematosus: results from two randomized, double-blind, placebo-controlled, multicentre studies (ALLEVIATE) and follow-up.
作者: Daniel J Wallace.;Caroline Gordon.;Vibeke Strand.;Kathryn Hobbs.;Michelle Petri.;Kenneth Kalunian.;Frederic Houssiau.;Paul P Tak.;David A Isenberg.;Lexy Kelley.;Brian Kilgallen.;Anna N Barry.;William A Wegener.;David M Goldenberg.
来源: Rheumatology (Oxford). 2013年52卷7期1313-22页
To evaluate epratuzumab treatment in patients with moderately-to-severely active SLE in two international, randomized, controlled trials (ALLEVIATE-1 and -2) and an open-label extension study (SL0006).
372. Rilonacept for gout flare prevention during initiation of uric acid-lowering therapy: results from the PRESURGE-2 international, phase 3, randomized, placebo-controlled trial.
作者: Essack Mitha.;H Ralph Schumacher.;Leon Fouche.;Shue-Fen Luo.;Steven P Weinstein.;George D Yancopoulos.;Jian Wang.;Shirletta King-Davis.;Robert R Evans.
来源: Rheumatology (Oxford). 2013年52卷7期1285-92页
To evaluate the efficacy and safety of IL-1 inhibitor rilonacept (IL-1 Trap) for gout flare (GF) prevention during initiation of uric acid-lowering therapy (ULT) with allopurinol in a multiregional phase 3 clinical trial.
373. Effects of subcutaneous and intravenous golimumab on inflammatory biomarkers in patients with rheumatoid arthritis: results of a phase 1, randomized, open-label trial.
作者: Mittie K Doyle.;Mahboob U Rahman.;Bart Frederick.;Charles A Birbara.;Dick de Vries.;Gary Toedter.;Xiaoying Wu.;Dion Chen.;Veena K Ranganath.;Mark E Westerman.;Daniel E Furst.
来源: Rheumatology (Oxford). 2013年52卷7期1214-9页
To evaluate the effects of the anti-TNF-α monoclonal antibody golimumab, administered by s.c. injection or i.v. infusion, on markers of inflammation in patients with RA.
374. Efficacy and safety of leflunomide in DMARD-naive patients with early rheumatoid arthritis: comparison of a loading and a fixed-dose regimen.
作者: Maurizio Cutolo.;Horatiu Bolosiu.;Gilles Perdriset.; .
来源: Rheumatology (Oxford). 2013年52卷6期1132-40页
To assess the efficacy of LEF administered with or without a loading dose in DMARD-naïve patients with early RA.
375. Effect on bone turnover markers of once-yearly intravenous infusion of zoledronic acid versus daily oral risedronate in patients treated with glucocorticoids.
作者: Jean-Pierre Devogelaer.;Philip Sambrook.;David M Reid.;Stefan Goemaere.;Sophia Ish-Shalom.;Julien Collette.;Guoqin Su.;Christina Bucci-Rechtweg.;Philemon Papanastasiou.;Jean-Yves Reginster.
来源: Rheumatology (Oxford). 2013年52卷6期1058-69页
Long-term glucocorticoid use is accompanied by rapid bone loss; however, early treatment with bisphosphonates prevents bone loss and reduces fracture risk. The aim of this study was to examine the effects of two bisphosphonates, i.v. zoledronic acid (ZOL) versus oral risedronate (RIS), on bone turnover markers (BTMs) in subjects with glucocorticoid-induced osteoporosis (GIO).
376. Ayurvedic medicine offers a good alternative to glucosamine and celecoxib in the treatment of symptomatic knee osteoarthritis: a randomized, double-blind, controlled equivalence drug trial.
作者: Arvind Chopra.;Manjit Saluja.;Girish Tillu.;Sanjeev Sarmukkaddam.;Anuradha Venugopalan.;Gumdal Narsimulu.;Rohini Handa.;Venil Sumantran.;Ashwinikumar Raut.;Lata Bichile.;Kalpana Joshi.;Bhushan Patwardhan.
来源: Rheumatology (Oxford). 2013年52卷8期1408-17页
To demonstrate clinical equivalence between two standardized Ayurveda (India) formulations (SGCG and SGC), glucosamine and celecoxib (NSAID).
377. Low-dose prednisolone in early rheumatoid arthritis inhibits collagen type I degradation by matrix metalloproteinases as assessed by serum 1CTP--a possible mechanism for specific inhibition of radiological destruction.
作者: Inga-Lill Engvall.;Björn Svensson.;Annelies Boonen.;Désirée van der Heijde.;Ulf H Lerner.;Ingiäld Hafström.; .
来源: Rheumatology (Oxford). 2013年52卷4期733-42页
To study the effects of low-dose prednisolone on the osteoclast-regulating proteins osteoprotegerin (OPG) and RANK ligand (RANKL) and on markers of bone resorption, 1CTP generated by MMPs and CTX-1 generated by cathepsin K, in patients with early RA in relation to inflammation and joint destruction.
378. Association between -871C>T promoter polymorphism in the B-cell activating factor gene and the response to rituximab in rheumatoid arthritis patients.
作者: Adeline Ruyssen-Witrand.;Stéphanie Rouanet.;Bernard Combe.;Maxime Dougados.;Xavier Le Loët.;Jean Sibilia.;Jacques Tebib.;Xavier Mariette.;Arnaud Constantin.
来源: Rheumatology (Oxford). 2013年52卷4期636-41页
To determine whether a functional single-nucleotide polymorphism in the B-cell activating factor (BAFF) gene correlates with the response to treatment with rituximab (RTX) in RA.
379. Treatment of complex regional pain syndrome type I with neridronate: a randomized, double-blind, placebo-controlled study.
作者: Massimo Varenna.;Silvano Adami.;Maurizio Rossini.;Davide Gatti.;Luca Idolazzi.;Francesca Zucchi.;Nazzarena Malavolta.;Luigi Sinigaglia.
来源: Rheumatology (Oxford). 2013年52卷3期534-42页
Complex regional pain syndrome type I (CRPS-I) is a severely disabling pain syndrome for which no definite treatment has been established. The aim of this multi-centre, randomized, double-blind placebo-controlled trial was to test the efficacy of the amino-bisphosphonate neridronate in patients with CRP-I.
380. The effect of foot orthoses on balance, foot pain and disability in elderly women with osteoporosis: a randomized clinical trial.
作者: Cecília de Morais Barbosa.;Manoel Barros Bértolo.;João Francisco Marques Neto.;Ibsen Bellini Coimbra.;Michael Davitt.;Eduardo de Paiva Magalhães.
来源: Rheumatology (Oxford). 2013年52卷3期515-22页
To evaluate the effect of insoles with medial arch support and metatarsal pad on balance, foot pain and disability in elderly women with osteoporosis.
|